Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moleculin Biotech reports robust Q1 results, eyes pivotal trials for growth

Moleculin Biotech's Q1 2024 earnings call highlighted strong performance of Annamycin, cost management, and strategic growth initiatives. Despite challenges with patient reactions and recruitment, the company is poised for value creation through upcoming trials and FDA interactions.

Moleculin Biotech excels in Q3 with promising AML drug

Moleculin Biotech's Q3 performance highlighted strong drug potential and financial stability
The company's adaptive trial design and global recruitment efforts position them for success
Challenges include meeting key milestones and addressing analyst inquiries for clarity
Opportunities lie in potential accelerated approval, strategic partnerships, and market expansion

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

HOUSTON, May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification...

Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

NEW YORK, May  18, 2020  (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional information requested" from the company. Trading in the company’s stock had been halted on May 4, 2020 at 9:25:06 Eastern Time at a last sale price of $1.07.

Nasdaq Halts Moleculin Biotech Inc.

CNS Pharmaceuticals

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company.

UPDATE: Moleculin Biotech, CNS Pharma     shares remain halted on Nasdaq

Moleculin Biotech Inc. MBRX, -1.83% said Monday its shares remain halted on Nasdaq with the exchange seeking additional information from the company.

Moleculin Biotech shares remain halted on Nasdaq

HOUSTON, May 18, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt of...

Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP1122 and its effect on COVID-19.

UPDATE: Moleculin Biotech and CNS Pharma comment on SEC trading halt

Moleculin Biotech Inc. MBRX, -1.83% said Monday it did not solicit or have any advance knowledge about claims made by third parties about its drug candidate WP1122 and its effect on COVID-19.

Moleculin Biotech did not solicit claims third parties made about a COVID-19 drug candidate that led to an SEC halt

Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.07, making no change from the previous trading session.

Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know

Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session

Moleculin Biotech Inc. (NASDAQ: MBRX) shares absolutely exploded on Wednesday after the company gave an update on its coronavirus treatment.

Why Moleculin Biotech’s Coronavirus Treatment Could Be Huge

Moleculin Biotech Inc (NASDAQ: MBRX) shares are trading higher on Wednesday, after the company said that independent research found 2-deoxy-D-glucose (2-DG) to reduce replication of coronavirus by 100% in the Vitro Testing.

Why Moleculin Biotech's Stock Is Trading Higher Today

Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

Moleculin Completes Enrollment in Early-Stage Cancer Study

Moleculin Biotech Inc (NASDAQ: MBRX) announced positive data Thursday from its Phase 1/2 study of annamycin in Poland.

Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

Moleculin Files New Patents for Cancer Candidate Annamycin

Moleculin Biotech Inc (NASDAQ: MBRX)'s stock was advancing Wednesday on heavy volume.

Moleculin Rallies On Patent Applications That Could Give Cancer Drug 20 Years of Protection

News for Moleculin Biotech Stock (MBRX)